[go: up one dir, main page]

AR121596A1 - Formas cristalinas de un agonista del receptor farnesoide x - Google Patents

Formas cristalinas de un agonista del receptor farnesoide x

Info

Publication number
AR121596A1
AR121596A1 ARP210100667A ARP210100667A AR121596A1 AR 121596 A1 AR121596 A1 AR 121596A1 AR P210100667 A ARP210100667 A AR P210100667A AR P210100667 A ARP210100667 A AR P210100667A AR 121596 A1 AR121596 A1 AR 121596A1
Authority
AR
Argentina
Prior art keywords
farnesoid
receptor agonist
crystalline forms
hydroxyazetidine
octan
Prior art date
Application number
ARP210100667A
Other languages
English (en)
Inventor
Nicholas D Smith
Robert Mansfield
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of AR121596A1 publication Critical patent/AR121596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una forma cristalina de 3-hidroxiazetidina-trans-1-carboxilato de 4-((4-(1-(tert-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi-3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexilo, o una sal o solvato farmacéuticamente aceptables de este. Reivindicación 2: La forma cristalina de la reivindicación 1, caracterizada por que la 3-hidroxiazetidina-trans-1-carboxilato de 4-((4-(1-(tert-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi-3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexilo es de base libre.
ARP210100667A 2020-03-18 2021-03-17 Formas cristalinas de un agonista del receptor farnesoide x AR121596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062991213P 2020-03-18 2020-03-18

Publications (1)

Publication Number Publication Date
AR121596A1 true AR121596A1 (es) 2022-06-22

Family

ID=77771306

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100667A AR121596A1 (es) 2020-03-18 2021-03-17 Formas cristalinas de un agonista del receptor farnesoide x

Country Status (13)

Country Link
US (1) US20230147756A1 (es)
EP (1) EP4121010A4 (es)
JP (2) JP7664278B2 (es)
KR (1) KR20220155356A (es)
CN (1) CN115666521A (es)
AR (1) AR121596A1 (es)
AU (1) AU2021236648A1 (es)
BR (1) BR112022018596A2 (es)
CA (1) CA3171987A1 (es)
IL (1) IL296532A (es)
MX (2) MX2022011582A (es)
TW (1) TW202144332A (es)
WO (1) WO2021188692A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
AU2021239956A1 (en) * 2020-03-18 2022-10-13 Eli Lilly And Company Formulations of a farnesoid X receptor agonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
SG11201908330PA (en) * 2017-03-15 2019-10-30 Metacrine Inc Farnesoid x receptor agonists and uses thereof
WO2020061116A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020061117A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
HRP20251321T1 (hr) * 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
US20220054469A1 (en) 2018-09-18 2022-02-24 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2021239956A1 (en) 2020-03-18 2022-10-13 Eli Lilly And Company Formulations of a farnesoid X receptor agonist
CN120732855A (zh) 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂

Also Published As

Publication number Publication date
BR112022018596A2 (pt) 2023-03-07
JP2023518399A (ja) 2023-05-01
US20230147756A1 (en) 2023-05-11
WO2021188692A1 (en) 2021-09-23
MX2025009319A (es) 2025-09-02
JP2025121901A (ja) 2025-08-20
CA3171987A1 (en) 2021-09-23
IL296532A (en) 2022-11-01
JP7664278B2 (ja) 2025-04-17
EP4121010A4 (en) 2024-04-10
KR20220155356A (ko) 2022-11-22
AU2021236648A1 (en) 2022-10-13
EP4121010A1 (en) 2023-01-25
MX2022011582A (es) 2022-12-13
CN115666521A (zh) 2023-01-31
TW202144332A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
AR121596A1 (es) Formas cristalinas de un agonista del receptor farnesoide x
AR117573A1 (es) Formas cristalinas de un inhibidor tlr7 / tlr8
MX376856B (es) Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
TWD214326S (zh) 氣溶膠產生裝置
JP1809070S (ja) ディスペンサー
AR078411A1 (es) Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
JP1733492S (ja) チェア
CL2022001173A1 (es) Forma cristalina de la base libre de un receptor del componente c5a del complemento
BRPI0512958A (pt) antagonistas de nk1
AU2017238918A8 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N- methylmethanamine salt
JP1743264S (ja) 殺菌剤ディスペンサー
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CL2022001241A1 (es) Antagonistas heterocíclicos de nmda
AR041455A1 (es) Combinacion de un inhibidor del factor xa y clopidogrel
JP1809078S (ja) ディスペンサー
CO5611134A2 (es) Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr
AR127545A1 (es) Formas cristalinas de un inhibidor de la monoacilglicerol lipasa
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
CO2025006877A2 (es) Compuesto que sirve como inhibidor de cinasa del receptor 1 del dominio de discoidina (ddr1) y medicamento
JP1715876S (ja) 家具用構成材
JP1720357S (ja) ラック用支柱
JP1789620S (ja) 歯ブラシ収納ケース
JP1704426S (ja) 消毒液ディスペンサー
JP1704428S (ja) 消毒液ディスペンサー

Legal Events

Date Code Title Description
FA Abandonment or withdrawal